TiGenix successfully renews GMP license for stem cell manufacturing facility in Madrid
(Thomson Reuters ONE) -
Regulated information
january 29, 2013
TiGenix successfully renews GMP license for stem cell manufacturing facility in
Madrid
Leuven (BELGIUM), Madrid (SPAIN) - January 29, 2013 - TiGenix (Euronext
Brussels: TIG), a leader in the field of cell therapy, announced today that
further to the cGMP inspection by the Spanish health authorities it has
successfully renewed its manufacturing authorization for stem cell products at
its manufacturing facility in Madrid, Spain.
"The GMP facility in Madrid performs a vital function within our organization by
manufacturing high-quality, clinical grade allogeneic stem cell products to fuel
our key clinical programs," said Wilfried Dalemans, CTO of TiGenix. "It is an
important stepping stone before we can move to commercial manufacturing at our
state-of-the-art, central GMP manufacturing site in Sittard-Geleen, the
Netherlands. Our strong cell therapy manufacturing capabilities place us at the
forefront of the cell therapy industry."
For more information:
Eduardo Bravo Claudia D'Augusta
Chief Executive Officer Chief Financial Officer
eduardo.bravo(at)tigenix.com claudia.daugusta(at)tigenix.com
Hans Herklots
hans.herklots(at)tigenix.com
+32 16 39 79 73
About TiGenix
TiGenix NV (Euronext Brussels: TIG) is a leading European cell therapy
company with a marketed product for cartilage repair, ChondroCelect®, and a
strong pipeline with clinical stage allogeneic adult stem cell programs for the
treatment of autoimmune and inflammatory diseases. TiGenix is based out of
Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen
(the Netherlands). For more information please visit www.tigenix.com.
Forward-looking information
This document may contain forward-looking statements and estimates with respect
to the anticipated future performance of TiGenix and the market in which it
operates. Certain of these statements, forecasts and estimates can be recognised
by the use of words such as, without limitation, "believes", "anticipates",
"expects", "intends", "plans", "seeks", "estimates", "may", "will" and
"continue" and similar expressions. They include all matters that are not
historical facts. Such statements, forecasts and estimates are based on various
assumptions and assessments of known and unknown risks, uncertainties and other
factors, which were deemed reasonable when made but may or may not prove to be
correct. Actual events are difficult to predict and may depend upon factors that
are beyond TiGenix' control. Therefore, actual results, the financial condition,
performance or achievements of TiGenix, or industry results, may turn out to be
materially different from any future results, performance or achievements
expressed or implied by such statements, forecasts and estimates. Given these
uncertainties, no representations are made as to the accuracy or fairness of
such forward-looking statements, forecasts and estimates. Furthermore, forward-
looking statements, forecasts and estimates only speak as of the date of the
publication of this document. TiGenix disclaims any obligation to update any
such forward-looking statement, forecast or estimates to reflect any change in
TiGenix' expectations with regard thereto, or any change in events, conditions
or circumstances on which any such statement, forecast or estimate is based,
except to the extent required by Belgian law.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: TiGenix via Thomson Reuters ONE
[HUG#1673722]
Unternehmensinformation / Kurzprofil:
Datum: 29.01.2013 - 07:01 Uhr
Sprache: Deutsch
News-ID 223720
Anzahl Zeichen: 4677
contact information:
Town:
Leuven
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 226 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"TiGenix successfully renews GMP license for stem cell manufacturing facility in Madrid"
steht unter der journalistisch-redaktionellen Verantwortung von
TiGenix (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
